Formycon setzt auf innovative Fertigspritze | Die Formycon AG (ISIN DE000A1EWVY8) bringt mit FYB201/Ranivisio das erste Ranibizumab-Biosimilar Europas als Fertigspritze auf den Markt. Der Münchner Biosimilar-Spezialist hat damit einen echten Vorsprung... ► Artikel lesen |
Formycon und Teva starten Vertrieb von FYB201-Fertigspritze | Die Formycon AG hat gemeinsam mit Bioeq und Teva Pharmaceutical Industries die Markteinführung von FYB201/Ranivisio, dem ersten in Europa zugelassenen Ranibizumab-Biosimilar in einer Fertigspritze,... ► Artikel lesen |
Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe | PETAH TIKVA (dpa-AFX) - Formycon AG (FYB.F), Bioeq AG and Teva Pharmaceutical Industries Ltd. (TEVA) on Tuesday announced the launch of FYB201/Ranivisio or ranibizumab in Europe as the first... ► Artikel lesen |
Kopin Corporation Announces Agreement for $15 Million Strategic Investment From Theon International Plc to Accelerate Global Defense Innovation |
Kopin gains significant access to the European and NATO defense market
Accelerates development of critical technologies
Further strengthens Kopin's balance sheet
Fixed conversion... ► Artikel lesen |
Kopin Corporation: Kopin to Showcase Portfolio of Spatial Light Modulators and Microdisplays at Laser World of Photonics 2025 | Kopin Corporation (NASDAQ: KOPN), a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical... ► Artikel lesen |
Kopin Corp. CFO Rich Sneider To Retire | WASHINGTON (dpa-AFX) - Kopin Corporation (KOPN) Thursday said its Chief Financial Officer, Rich Sneider is retiring, and has commenced a search to find a replacement.Sneider is expected to remain... ► Artikel lesen |